Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa : a retrospective cohort analysis
Date
2019-10-17
Journal Title
Journal ISSN
Volume Title
Publisher
Public Library of Science
Abstract
ENGLISH ABSTRACT: South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.
Description
CITATION: Bouton, T. C., et al. 2019. Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa : a retrospective cohort analysis. PLoS ONE, 14(10). doi:10.1371/journal.pone.0223308
The original publication is available at https://journals.plos.org/plosone/
The original publication is available at https://journals.plos.org/plosone/
Keywords
Tuberculosis -- Treatment, Bedaquiline (BDQ), Antibiotics, Rifampicin, Multidrug-resistant tuberculosis
Citation
Bouton, T. C., et al. 2019. Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa : a retrospective cohort analysis. PLoS ONE, 14(10). doi:10.1371/journal.pone.0223308